MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research a...( MOUNTAIN VIEW Calif. July 16 /- M...),Health

MOUNTAIN VIEW, Calif., July 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the positive results from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics were published in the July issue of Current Medical Research and Opinion. MAP Pharmaceuticals is developing MAP0004, an orally inhaled and self-administered therapy, as a potential treatment for migraine.

The study results, which were first announced last year, demonstrated that treatment with MAP0004 resulted in rapid and efficient systemic absorption of the therapeutic compound, dihydroergotamine (DHE), in asthmatic subjects, and that absorption was comparable to that observed in a previous study of healthy volunteers.

"Asthma and migraine have a high incidence of co-morbidity, so it was important to evaluate MAP0004 in patients with compromised pulmonary function," said Thomas A. Armer, Ph.D., chief scientific officer of MAP Pharmaceuticals. "In the study, MAP0004 was well tolerated by asthmatics with no effect on pulmonary function and with no serious adverse events reported."

About the Phase 2 Study

The Phase 2 study was a randomized, double-blind, placebo-controlled, crossover study of MAP0004 in 19 adult asthmatics. Each patient received three doses, one every week in randomized order over a 15-day period, including two 1.0 mg doses of MAP0004 and one dose of placebo. The 1.0 mg dose is twice the dose being studied in MAP Pharmaceuticals' Phase 3 trial. Spirometry was performed and blood draws were obtained at screening and at multiple times during each visit.

The study indicated that MAP0004 was well tolerated by subjects with compromised lung function, and
'/>"/>